OBJECTIVE: Patients with gout have lower calcitriol levels that improve when uric acid is lowered. The mechanism of these observations is unknown. We hypothesized that uric acid inhibits 1-αhydroxylase. MATERIALS AND METHODS: In vivo, Sprague Dawley rats were randomized to control (n = 5), allantoxanamide (n=8), febuxostat (n=5), or allantoxanamide+febuxostat (n = 7). Vitamin D, PTH, and 1-αhydroxylase protein were evaluated. In order to directly evaluate the effect of uric acid on 1-αhydroxylase, we conducted a series of dose response and time course experiments in vitro. Nuclear factor κ-B (NFκB) was inhibited pharmacologically. Finally, to evaluate the potential implications of these findings in humans, the association between uric acid and PTH in humans was evaluated in a cross-sectional analysis of data from the NHANES (2003-2006); n = 9773. RESULTS: 1,25(OH)2D and 1-αhydroxylase protein were reduced in hyperuricemic rats and improved with febuxostat treatment. Uric acid suppressed 1-αhydroxylase protein and mRNA expression in proximal tubular cells. This was prevented by NFκB inhibition. In humans, for every 1mg/dL increase in uric acid, the adjusted odds ratio for an elevated PTH (>65 pg/mL) was 1.21 (95% C.I. 1.14, 1.28; P<0.0001), 1.15 (95% C.I. 1.08, 1.22; P<0.0001), and 1.16 (95% C.I. 1.03, 1.31; P = 0.02) for all subjects, subjects with estimated GFR ≥ 60, and subjects with estimated GFR <60 mL/min/1.73 m(2) respectively. CONCLUSION: Hyperuricemia suppresses 1-αhydroxylase leading to lower 1,25(OH)2D and higher PTH in rats. Our results suggest this is mediated by NFκB. The association between uric acid and PTH in NHANES suggests potential implications for human disease.
OBJECTIVE:Patients with gout have lower calcitriol levels that improve when uric acid is lowered. The mechanism of these observations is unknown. We hypothesized that uric acid inhibits 1-αhydroxylase. MATERIALS AND METHODS: In vivo, Sprague Dawley rats were randomized to control (n = 5), allantoxanamide (n=8), febuxostat (n=5), or allantoxanamide+febuxostat (n = 7). Vitamin D, PTH, and 1-αhydroxylase protein were evaluated. In order to directly evaluate the effect of uric acid on 1-αhydroxylase, we conducted a series of dose response and time course experiments in vitro. Nuclear factor κ-B (NFκB) was inhibited pharmacologically. Finally, to evaluate the potential implications of these findings in humans, the association between uric acid and PTH in humans was evaluated in a cross-sectional analysis of data from the NHANES (2003-2006); n = 9773. RESULTS:1,25(OH)2D and 1-αhydroxylase protein were reduced in hyperuricemicrats and improved with febuxostat treatment. Uric acid suppressed 1-αhydroxylase protein and mRNA expression in proximal tubular cells. This was prevented by NFκB inhibition. In humans, for every 1mg/dL increase in uric acid, the adjusted odds ratio for an elevated PTH (>65 pg/mL) was 1.21 (95% C.I. 1.14, 1.28; P<0.0001), 1.15 (95% C.I. 1.08, 1.22; P<0.0001), and 1.16 (95% C.I. 1.03, 1.31; P = 0.02) for all subjects, subjects with estimated GFR ≥ 60, and subjects with estimated GFR <60 mL/min/1.73 m(2) respectively. CONCLUSION:Hyperuricemia suppresses 1-αhydroxylase leading to lower 1,25(OH)2D and higher PTH in rats. Our results suggest this is mediated by NFκB. The association between uric acid and PTH in NHANES suggests potential implications for human disease.
Keywords:
1,25 dihydroxy-vitamin D; 1,25(OH)(2)D; 25 hydroxyvitamin D; 25(OH)D; ATX; BMI; CKD; FBXT; GFR; IQR; MBD; MDRD; Mineral and bone disorder; Mineral and bone disorders; Modification of Diet in Renal Disease; NFκB; NHANES; National Health and Nutrition Examination Survey; PTH; Parathyroid hormone; Uric acid; allantoxanamide; body mass index; chronic kidney disease; febuxostat; glomerular filtration rate; inter-quartile range; nuclear factor κ- B; parathyroid hormone
Authors: A S Levey; R Atkins; J Coresh; E P Cohen; A J Collins; K-U Eckardt; M E Nahas; B L Jaber; M Jadoul; A Levin; N R Powe; J Rossert; D C Wheeler; N Lameire; G Eknoyan Journal: Kidney Int Date: 2007-06-13 Impact factor: 10.612
Authors: Peter A McCullough; Claudine T Jurkovitz; Pablo E Pergola; Janet B McGill; Wendy W Brown; Alan J Collins; Shu-Cheng Chen; Suying Li; Ajay Singh; Keith C Norris; Michael J Klag; George L Bakris Journal: Arch Intern Med Date: 2007-06-11
Authors: Julie M Paik; Seoyoung C Kim; Diane Feskanich; Hyon K Choi; Daniel H Solomon; Gary C Curhan Journal: Arthritis Rheumatol Date: 2017-02 Impact factor: 10.995
Authors: Baris Afsar; Alan A Sag; Cinar Oztosun; Masanari Kuwabara; Mario Cozzolino; Adrian Covic; Mehmet Kanbay Journal: J Nephrol Date: 2019-04-27 Impact factor: 3.902
Authors: Miguel A Lanaspa; Ana Andres-Hernando; David J Orlicky; Christina Cicerchi; Cholsoon Jang; Nanxing Li; Tamara Milagres; Masanari Kuwabara; Michael F Wempe; Joshua D Rabinowitz; Richard J Johnson; Dean R Tolan Journal: J Clin Invest Date: 2018-04-23 Impact factor: 14.808
Authors: M Pirro; M R Mannarino; V Bianconi; S De Vuono; A Sahebkar; F Bagaglia; L Franceschini; A M Scarponi; E Mannarino; T Merriman Journal: Osteoporos Int Date: 2016-10-10 Impact factor: 4.507
Authors: Tapan Mehta; Petra Bůžková; Mark J Sarnak; Michel Chonchol; Jane A Cauley; Erin Wallace; Howard A Fink; John Robbins; Diana Jalal Journal: Metabolism Date: 2014-11-21 Impact factor: 8.694
Authors: Savas Sipahi; Seyyid Bilal Acikgoz; Ahmed Bilal Genc; Mehmet Yildirim; Yalcin Solak; Ali Tamer Journal: Med Princ Pract Date: 2016-12-06 Impact factor: 1.927